=>
Uploading C:\Program Files\Stnexp\Queries\308.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




Structure attributes must be viewed using STN Express query preparation.

```
=> d his full

     (FILE 'HOME' ENTERED AT 23:38:56 ON 17 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 23:39:05 ON 17 MAR 2006
L1             STRUCTURE UPLOADED
               D L1
L2           1 SEA SSS SAM L1
               D L2 1
L3          31 SEA SSS FUL L1

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 23:40:00 ON 17 MAR 2006
L4          67 SEA L3
L5           7 SEA L4 AND (AUTO(W) IMMUN? OR AUTOIMMUN? OR MULTIPLE(2A)
               SCLERO? OR LUPU? OR ARTHRIT? OR ENCEPHALOMYELIT? OR UVEI?)
L6           6 DUP REM L5 (1 DUPLICATE REMOVED)
               D L6 ABS CBIB KWIC HITSTR 1-6

     FILE 'STNGUIDE' ENTERED AT 23:41:59 ON 17 MAR 2006
               D QUE STAT


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   16 MAR 2006  HIGHEST RN 877118-69-9
     DICTIONARY FILE UPDATES:  16 MAR 2006  HIGHEST RN 877118-69-9

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE HCAPLUS
```

FILE COVERS 1907 - 17 Mar 2006 VOL 144 ISS 13
FILE LAST UPDATED: 16 Mar 2006 (20060316/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 16 Mar 2006 (20060316/PD)
FILE LAST UPDATED: 16 Mar 2006 (20060316/ED)
HIGHEST GRANTED PATENT NUMBER: US7013485
HIGHEST APPLICATION PUBLICATION NUMBER: US2006059596
CA INDEXING IS CURRENT THROUGH 16 Mar 2006 (20060316/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 16 Mar 2006 (20060316/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 10, 2006 (20060310/UP).

=>

FILE 'HCAPLUS' ENTERED AT 23:40:00 ON 17 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 23:40:00 ON 17 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l3
L4 67 L3

=> s l4 and (auto(w)immun? or autoimmun? or multiple(2a)sclero? or lupu? or arthrit? or encephalomyelit? or uvei?)
L5 7 L4 AND (AUTO(W) IMMUN? OR AUTOIMMUN? OR MULTIPLE(2A) SCLERO? OR LUPU? OR ARTHRIT? OR ENCEPHALOMYELIT? OR UVEI?)

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6 6 DUP REM L5 (1 DUPLICATE REMOVED)

=> d l6 abs cbib kwic hitstr 1-6

L6 ANSWER 1 OF 6 USPATFULL on STN
AB The present invention discloses a method for treating a subject affected by an **autoimmune** disease, in particular **multiple sclerosis**, **lupus** erythematosus systemicus and rheumatoid **arthritis**, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-methoxy-1H-1,2,4-tirazole. The present invention further discloses a method for inhibiting γδ T cells in a subject in need thereof, said method comprising administering to said subject an effective amount of the same compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
2005:31543 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole for the treatment of **autoimmune** diseases.
Battistini, Luca, Pomezia, ITALY
Borsellino, Giovanna, Pomezia, ITALY
De Santis, Rita, Pomezia, ITALY
Carminati, Paolo, Pomezia, ITALY
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome, ITALY (non-U.S. corporation)
US 2005026980 A1 20050203
APPLICATION: US 2004-812308 A1 20040330 (10)
DOCUMENT TYPE: Utility; APPLICATION.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole for the treatment of **autoimmune** diseases
AB The present invention discloses a method for treating a subject affected by an **autoimmune** disease, in particular **multiple sclerosis**, **lupus** erythematosus systemicus and rheumatoid **arthritis**, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-methoxy-1H-1,2,4-tirazole. The present invention further discloses a method for inhibiting γδ. . .
SUMM [0001] The present invention relates to a method for the treatment of **autoimmune** diseases, which are effectively treated by administering the compound (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-

[1,2,4]-triazole.

SUMM [0002] **Multiple sclerosis** (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) that is thought to be mediated by an **autoimmune** attack directed against CNS myelin antigens. Based on animal models, as well as on data gathered from analyses of leukocytes. . .

SUMM . . . been found that a compound of the 3,5-diaryl-s-triazoles class of molecules, more precisely (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole (hereinafter also called ST1959) efficiently treats **autoimmune** diseases. It has also been found that the compound according to the present invention inhibits the γδ T cell effector. . .

SUMM [0013] Accordingly, it is an object of the present invention a method for treating a subject affected by an **autoimmune** disease comprising administering to said subject an effective amount of (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole

SUMM [0014] In particular, according to the method of the present invention, said subject is affected by an **autoimmune** disease, such as **multiple sclerosis**, **lupus** erythematosus sistemicus, **arthritis** reumatoid (RA).

SUMM . . . Immunopharmacology, vol. 10, 1985, 163-169. In this reference, the compound of the present invention showed to be inactive in treating **arthritis**.

DETD **Multiple Sclerosis**

DETD **Lupus**

DETD [0031] Mice MRL/lpr (female) of about 6 weeks were obtained from Jackson (USA). These mice spontaneously develop a **Lupus** like pathology around the 8th week. ST1959 administration was started at the 6th week and performed s.c. twice/week 2.5 mg/kg. . .

DETD Collagen Induced **Arthritis**

DETD [0032] Mice DBA/1J were obtained from Charles Rivers (Italy). Induction of **arthritis** was performed by administration, at day 0 and +21 of 100 μl/mouse i.d. of emulsions composed of equal volumes of. . .

DETD Experimental **Autoimmune Encephalomyelitis** (EAE)

DETD Experimental **Autoimmune Uveitis** (EAU)

CLM What is claimed is:

9. A method for treating **uveitis** in a subject in need thereof, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole.

IT **69095-83-6**, 3-(2-Ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole
((ethylphenyl)methoxytriazole for treatment of autoimmune diseases)

IT **69095-83-6**, 3-(2-Ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole
((ethylphenyl)methoxytriazole for treatment of autoimmune diseases)

RN 69095-83-6 USPATFULL

CN 1H-1,2,4-Triazole, 3-(2-ethylphenyl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
AB The present invention discloses a method for treating a subject affected by an **autoimmune** disease, in particular **multiple sclerosis**, **lupus** erythematosus systemicus and rheumatoid **arthritis**, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole. The present invention further discloses a method for inhibiting T cells in a subject in need thereof, said method comprising administering to said subject an effective amount of the same compound
2003:874976 Document Number 139:345916 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of **autoimmune** diseases. Battistini, Luca; Borsellino, Giovanna; De Santis, Rita; Carminati, Paolo (Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., USA). U.S. Pat. Appl. Publ. US 2003207931 A1 20031106, 11 pp. (English). CODEN: USXXCO. APPLICATION: US 2002-137699 20020503.
TI Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of **autoimmune** diseases
AB The present invention discloses a method for treating a subject affected by an **autoimmune** disease, in particular **multiple sclerosis**, **lupus** erythematosus systemicus and rheumatoid **arthritis**, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole. The present invention further discloses a method for inhibiting T. . .
ST ethylphenylmethoxytriazole **autoimmune** disease treatment
IT Antiarthritics
Antirheumatic agents
**Autoimmune** disease
Human
**Multiple sclerosis**
Rheumatoid **arthritis**
((ethylphenyl)methoxytriazole for treatment of **autoimmune** diseases)
IT **Lupus** erythematosus
(systemic; (ethylphenyl)methoxytriazole for treatment of **autoimmune** diseases)
IT T cell (lymphocyte)
(γδ; (ethylphenyl)methoxytriazole for treatment of **autoimmune** diseases)
IT **69095-83-6**, 3-(2-Ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
((ethylphenyl)methoxytriazole for treatment of **autoimmune** diseases)
IT **69095-83-6**, 3-(2-Ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
((ethylphenyl)methoxytriazole for treatment of **autoimmune** diseases)
RN 69095-83-6 HCAPLUS
CN 1H-1,2,4-Triazole, 3-(2-ethylphenyl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

AB ST1959, formerly known as DL111-IT, is a contragestional agent of the triazole family, which has previously been reported to exhibit immunomodulatory activity. The present study aimed to evaluate the therapeutic potential of ST1959 in murine **autoimmunity** models. We selected MRL/lpr mice, which develop a syndrome that is serol. and pathol. similar to human systemic **lupus** erythematosus and collagen-induced **arthritis** in mice and which resembles human rheumatoid **arthritis**. S.c. administration of ST1959 improved clin. scores in both models and increased survival in the case of **lupus**. To gain further insight into the possible mechanisms of action of ST1959, its effects on lymphoid organs were studied in comparison with the reference compds. cyclosporin A (Sandimmun) and leflunomide (Arava) in normal Lewis rats. A dramatic decrease in thymus weight and cellularity was observed in animals treated with ST1959 and leflunomide, while the effect of cyclosporin A was marginal. The thymus subpopulations were also differently affected as the percentage of double-neg. cells was approx. doubled by ST1959 and leflunomide but not by cyclosporin A. The percentage of double-pos. cells was reduced by ST1959 and leflunomide, and the percentage of CD4+ or CD8+ single-pos. cells was almost doubled in rats treated with either ST1959 or leflunomide, while opposite effects were observed with cyclosporin A. Unlike leflunomide, and cyclosporin A, ST1959 induced an increase of single-pos. CD3+high cells that correlated with an increased mitogen-induced proliferation of thymocytes. Overall, these findings suggest a peculiar immunomodulatory profile for ST1959.

2004:250954 Document Number 141:254027 Efficacy of ST1959 in murine models of **autoimmunity** and insights into its peculiar immunomodulatory profile. Ruggiero, V.; Albertoni, C.; Rosi, A.; Leoni, B.; Carminati, P.; De Santis, R. (Research and Development, Department of Immunology, Sigma-tau SpA, Pomezia, 00040, Italy). International Journal of Immunotherapy, 19(1), 1-10 (English) 2003. CODEN: IJIMET. ISSN: 0255-9625. Publisher: Bioscience Ediprint Inc..

TI Efficacy of ST1959 in murine models of **autoimmunity** and insights into its peculiar immunomodulatory profile

AB . . . previously been reported to exhibit immunomodulatory activity. The present study aimed to evaluate the therapeutic potential of ST1959 in murine **autoimmunity** models. We selected MRL/lpr mice, which develop a syndrome that is serol. and pathol. similar to human systemic **lupus** erythematosus and collagen-induced **arthritis** in mice and which resembles human rheumatoid **arthritis**. S.c. administration of ST1959 improved clin. scores in both models and increased survival in the case of **lupus**. To gain further insight into the possible mechanisms of action of ST1959, its effects on lymphoid organs were studied in. . .

ST **autoimmunity** immunomodulator cyclosporin leflunomide **lupus** nephropathy **arthritis**; thymus thymocyte maturation proliferation immunosuppressant ST1959

IT **Autoimmune** disease

(**autoimmune arthritis**; s.c. ST1959 effectively delayed onset of inflammatory lesions, joint ankylosis and produced overall reduction in clin. severity of joint disease in CIA DBA/1J mouse model)

IT **Arthritis**
(**autoimmune**; s.c. ST1959 effectively delayed onset of inflammatory lesions, joint ankylosis and produced overall reduction in clin. severity of joint disease in CIA DBA/1J mouse model)

IT Immunity
(**autoimmunity**; s.c. ST1959 improved clin. scores in both **lupus** nephropathy MRL/lpr mouse model and CIA DBA/1J mouse model, increased survival in case of **lupus** and dose-dependently decreased thymus weight and cellularity in normal rat)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proteinuria; s.c. ST1959 was effective in counteracting rise of renal dysfunction marker protein levels in urine in **lupus** nephropathy MRL/lpr mouse model)

IT Immunomodulators
(s.c. ST1959 showed beneficial effects in murine models of **autoimmunity** and had peculiar immunomodulatory profile in rat)

IT Kidney
(s.c. ST1959 was effective in counteracting rise of protein and leukocyte levels in urine and not only delayed onset of mortality, but also increased overall survival in **lupus** nephropathy MRL/lpr mouse model without toxicity)

IT Leukocyte
(s.c. ST1959 was effective in counteracting rise of renal dysfunction marker leukocyte levels in urine in **lupus** nephropathy MRL/lpr mouse model)

IT **Lupus** erythematosus
(systemic; s.c. ST1959 was effective in counteracting rise of protein and leukocyte levels in urine and not only delayed onset of mortality, but also increased overall survival in **lupus** nephropathy MRL/lpr mouse model without toxicity)

IT **69095-83-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(S.C. ST1959 dose-dependently decreased thymus weight, cellularity, CD4+CD8+ T-cells, enhanced thymocyte proliferation, dose-dependently increased CD4+CD8-, CD4-CD8+, increased single-pos. CD3+high T-cells in rat)

IT **69095-83-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(S.C. ST1959 dose-dependently decreased thymus weight, cellularity, CD4+CD8+ T-cells, enhanced thymocyte proliferation, dose-dependently increased CD4+CD8-, CD4-CD8+, increased single-pos. CD3+high T-cells in rat)

RN 69095-83-6 HCAPLUS

CN 1H-1,2,4-Triazole, 3-(2-ethylphenyl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 4 OF 6 USPATFULL on STN

AB Compounds of formula (I), wherein X and Y are independently carbon or nitrogen but not both simultaneously carbon, R.sub.1 is a group (II) and R.sub.2 is a group (III), R.sub.5 being a carbonate, carbamate or phosphate residue, are useful as anti-gestative, immuno-suppressant and anti-tumor agents ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

2001:235266 Diphenyl-triazole derivatives and their use as anti-gestative, immuno-suppressant and anti-tumoral agents.
Rossi, Carla, Milan, Italy
Geange Ltd., Dublin, Ireland (non-U.S. corporation)
US 6333343 B1 20011225
WO 9855463 19981210
APPLICATION: US 2000-445218 20000128 (9)
WO 1998-EP3496 19980604 20000128 PCT 371 date 20000128 PCT 102(e) date
PRIORITY: IT 1997-MI1328 19970605
DOCUMENT TYPE: Utility; GRANTED.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . immunity when administered during the inductive phase of the immuno response, i.e. soon after antigen challenge. In experimental models of **auto-immunity** and skin transplantation they were able to reduce auto-antibody production as well as to prolong the skin graft survival.

IT 216854-85-2P 216854-87-4P 216854-91-0P 216854-97-6P 216855-02-6P 216855-07-1P **216855-11-7P**
(preparation of diphenyltriazoles as antigestative, immunosuppressant, and antitumor agents)

IT **216855-11-7P**
(preparation of diphenyltriazoles as antigestative, immunosuppressant, and antitumor agents)

RN 216855-11-7 USPATFULL

CN Carbonic acid, [2-[5-(3-methoxyphenyl)-1H-1,2,4-triazol-3-yl]phenyl]methyl octyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

GI



I

AB The title compds., (R = H, alkyl, etc.; R1 = H, alkyl, OMe, etc.) were disclosed as inflammation inhibitors and/or immune modulators. Use of I for the treatment of psoriasis, inflammatory bowel disease and rheumatoid **arthritis** was claimed.

1994:605364 Document Number 121:205364 5H-[1,2,4]Triazolo[5,1-a]isoindol-5-ones as inflammation inhibitors and immunomodulators. Albrechtsen, Sten; Hansen, Jens; Langvad, Eyvind; Eriksoo, Edgar; Johansson, Kaj; Lundvall, Karl-Erik (British Technology Group Ltd., UK). PCT Int. Appl. WO 9417068 A1 19940804, 25 pp. DESIGNATED STATES: W: AU, CA, JP, KR, NZ, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1994-IB10 19940118. PRIORITY: SE 1993-127 19930119.

AB . . . disclosed as inflammation inhibitors and/or immune modulators. Use of I for the treatment of psoriasis, inflammatory bowel disease and rheumatoid **arthritis** was claimed.

ST triazoloisoindolone prepn inflammation inhibitor; psoriasis triazoloisoindolone prepn inflammation inhibitor; rheumatoid **arthritis** triazoloisoindolone prepn inflammation inhibitor; inflammatory bowel disease triazoloisoindolone prepn

IT 85-44-9, Phthalic anhydride 1005-02-3, 2-Pyridyl amidrazone 60510-58-9, Benzoic acid, 2-(5-phenyl-1H-1,2,4-triazol-3-yl)- 75704-77-7, Benzoic acid, 2-[5-[3-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]- **92085-32-0**, Benzoic acid, 2-[5-(3-methoxyphenyl)-1H-1,2,4-triazol-3-yl]- 157929-34-5, 2-[5-(4-Methoxyphenyl)-1H-1,2,4-triazol-3-yl]benzoic acid 157929-35-6, 2-[5-(4-Chlorophenyl)-1H-1,2,4-triazol-3-yl]benzoic acid 157929-36-7, 4-Methoxy-2-(5-phenyl-1H-1,2,4-triazol-3-yl)benzoic acid 157929-37-8, 3-Fluoro-2-(5-phenyl-1H-1,2,4-triazol-3-yl)benzoic acid 157929-38-9, 5-Chloro-2-[5-(4-hydroxyphenyl)-1H-1,2,4-triazol-3-yl]benzoic acid 157929-39-0, 2-[5-(4-Fluorophenyl)-1H-1,2,4-triazol-3-yl]benzoic acid **157929-40-3**, 2-[5-(3,4-Dimethoxyphenyl)-1H-1,2,4-triazol-3-yl]benzoic acid 157929-41-4, 2-(5-Phenyl-1H-1,2,4-triazol-3-yl]-4-(trifluoromethyl)benzoic acid 157929-42-5, 5-(Dimethylamino)-2-(5-Phenyl-1H-1,2,4-triazol-3-yl]benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [1,2,4]triazolo[5,1-a]isoindolone inflammation inhibitor)

IT **92085-32-0**, Benzoic acid, 2-[5-(3-methoxyphenyl)-1H-1,2,4-triazol-3-yl]- **157929-40-3**, 2-[5-(3,4-Dimethoxyphenyl)-1H-1,2,4-triazol-3-yl]benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for [1,2,4]triazolo[5,1-a]isoindolone inflammation inhibitor)

RN 92085-32-0 HCAPLUS

CN Benzoic acid, 2-[5-(3-methoxyphenyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)



RN 157929-40-3 HCAPLUS
CN Benzoic acid, 2-[5-(3,4-dimethoxyphenyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB The immunosuppressive properties of the nonhormonal contragestional agent DL111-IT (I) [**69095-83-6**] were evaluated on different immunol. functions. The compound displayed significant immunosuppressive activity on both humoral and cellular immunity when administered during the inductive phase of the immune response. In exptl. models of **autoimmunity** and skin transplantation, I reduced the production of autoantibodies and prolonged skin graft survival. The compound, even at doses much higher than those effective in inhibiting immune responses, did not influence the survival time of some hematol. tumors in mice, suggesting that I does not act by a general cytotoxic mechanism.

1986:102143 Document Number 104:102143 Immunological profile of DL111-IT, a new immunosuppressant agent. Mistrello, Giovanni; Galliani, Giulio; Assandri, Alessandro; Filippeschi, Stefania; Bassi, Luigi (Laboratory Immunol., Gruppo Lepetit S.p.A., Milan, 20158, Italy). Immunopharmacology, 10(3), 163-9 (English) 1985. CODEN: IMMUDP. ISSN: 0162-3109.

AB The immunosuppressive properties of the nonhormonal contragestional agent DL111-IT (I) [**69095-83-6**] were evaluated on different immunol. functions. The compound displayed significant immunosuppressive activity on both humoral and cellular immunity when administered during the inductive phase of the immune response. In exptl. models of **autoimmunity**

and skin transplantation, I reduced the production of autoantibodies and prolonged skin graft survival. The compound, even at doses much. . .

IT **69095-83-6**
RL: BIOL (Biological study)
(immunosuppression by, profile of)

IT **69095-83-6**
RL: BIOL (Biological study)
(immunosuppression by, profile of)

RN 69095-83-6 HCAPLUS
CN 1H-1,2,4-Triazole, 3-(2-ethylphenyl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)